α-lipoic acid as a triglyceride-lowering nutraceutical

Anjeza Pashaj, Mengna Xia, Regis F Moreau

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Considering the current obesity epidemic in the United States (>100 million adults are overweight or obese), the prevalence of hypertriglyceridemia is likely to grow beyond present statistics of~30% of the population. Conventional therapies for managing hypertriglyceridemia include lifestyle modifications such as diet and exercise, pharmacological approaches, and nutritional supplements. It is critically important to identify new strategies that would be safe and effective in lowering hypertriglyceridemia. a-Lipoic acid (LA) is a naturally occurring enzyme cofactor found in the human body in small quantities. A growing body of evidence indicates a role of LA in ameliorating metabolic dysfunction and lipid anomalies primarily in animals. Limited human studies suggest LA is most efficacious in situations where blood triglycerides are markedly elevated. LA is commercially available as dietary supplements and is clinically shown to be safe and effective against diabetic polyneuropathies. LA is described as a potent biological antioxidant, a detoxification agent, and a diabetes medicine. Given its strong safety record, LA may be a useful nutraceutical, either alone or in combination with other lipid-lowering strategies, when treating severe hypertriglyceridemia and diabetic dyslipidemia. This review examines the current evidence regarding the use of LA as a means of normalizing blood triglycerides. Also presented are the leading mechanisms of action of LA on triglyceride metabolism.

Original languageEnglish (US)
Pages (from-to)1029-1041
Number of pages13
JournalCanadian Journal of Physiology and Pharmacology
Volume93
Issue number12
DOIs
StatePublished - Sep 25 2015

Fingerprint

Thioctic Acid
Dietary Supplements
Triglycerides
Hypertriglyceridemia
Lipids
Diabetic Neuropathies
Coenzymes
Population Characteristics
Dyslipidemias
Human Body
Life Style
Obesity
Antioxidants
Medicine
Pharmacology
Diet
Safety

Keywords

  • AMPK
  • ChREBP
  • FGF21
  • PPARα
  • SREBP1

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Pharmacology

Cite this

α-lipoic acid as a triglyceride-lowering nutraceutical. / Pashaj, Anjeza; Xia, Mengna; Moreau, Regis F.

In: Canadian Journal of Physiology and Pharmacology, Vol. 93, No. 12, 25.09.2015, p. 1029-1041.

Research output: Contribution to journalArticle

@article{a2bc12175023444eb32cb92f8bbcb676,
title = "α-lipoic acid as a triglyceride-lowering nutraceutical",
abstract = "Considering the current obesity epidemic in the United States (>100 million adults are overweight or obese), the prevalence of hypertriglyceridemia is likely to grow beyond present statistics of~30{\%} of the population. Conventional therapies for managing hypertriglyceridemia include lifestyle modifications such as diet and exercise, pharmacological approaches, and nutritional supplements. It is critically important to identify new strategies that would be safe and effective in lowering hypertriglyceridemia. a-Lipoic acid (LA) is a naturally occurring enzyme cofactor found in the human body in small quantities. A growing body of evidence indicates a role of LA in ameliorating metabolic dysfunction and lipid anomalies primarily in animals. Limited human studies suggest LA is most efficacious in situations where blood triglycerides are markedly elevated. LA is commercially available as dietary supplements and is clinically shown to be safe and effective against diabetic polyneuropathies. LA is described as a potent biological antioxidant, a detoxification agent, and a diabetes medicine. Given its strong safety record, LA may be a useful nutraceutical, either alone or in combination with other lipid-lowering strategies, when treating severe hypertriglyceridemia and diabetic dyslipidemia. This review examines the current evidence regarding the use of LA as a means of normalizing blood triglycerides. Also presented are the leading mechanisms of action of LA on triglyceride metabolism.",
keywords = "AMPK, ChREBP, FGF21, PPARα, SREBP1",
author = "Anjeza Pashaj and Mengna Xia and Moreau, {Regis F}",
year = "2015",
month = "9",
day = "25",
doi = "10.1139/cjpp-2014-0480",
language = "English (US)",
volume = "93",
pages = "1029--1041",
journal = "Canadian Journal of Physiology and Pharmacology",
issn = "0008-4212",
publisher = "National Research Council of Canada",
number = "12",

}

TY - JOUR

T1 - α-lipoic acid as a triglyceride-lowering nutraceutical

AU - Pashaj, Anjeza

AU - Xia, Mengna

AU - Moreau, Regis F

PY - 2015/9/25

Y1 - 2015/9/25

N2 - Considering the current obesity epidemic in the United States (>100 million adults are overweight or obese), the prevalence of hypertriglyceridemia is likely to grow beyond present statistics of~30% of the population. Conventional therapies for managing hypertriglyceridemia include lifestyle modifications such as diet and exercise, pharmacological approaches, and nutritional supplements. It is critically important to identify new strategies that would be safe and effective in lowering hypertriglyceridemia. a-Lipoic acid (LA) is a naturally occurring enzyme cofactor found in the human body in small quantities. A growing body of evidence indicates a role of LA in ameliorating metabolic dysfunction and lipid anomalies primarily in animals. Limited human studies suggest LA is most efficacious in situations where blood triglycerides are markedly elevated. LA is commercially available as dietary supplements and is clinically shown to be safe and effective against diabetic polyneuropathies. LA is described as a potent biological antioxidant, a detoxification agent, and a diabetes medicine. Given its strong safety record, LA may be a useful nutraceutical, either alone or in combination with other lipid-lowering strategies, when treating severe hypertriglyceridemia and diabetic dyslipidemia. This review examines the current evidence regarding the use of LA as a means of normalizing blood triglycerides. Also presented are the leading mechanisms of action of LA on triglyceride metabolism.

AB - Considering the current obesity epidemic in the United States (>100 million adults are overweight or obese), the prevalence of hypertriglyceridemia is likely to grow beyond present statistics of~30% of the population. Conventional therapies for managing hypertriglyceridemia include lifestyle modifications such as diet and exercise, pharmacological approaches, and nutritional supplements. It is critically important to identify new strategies that would be safe and effective in lowering hypertriglyceridemia. a-Lipoic acid (LA) is a naturally occurring enzyme cofactor found in the human body in small quantities. A growing body of evidence indicates a role of LA in ameliorating metabolic dysfunction and lipid anomalies primarily in animals. Limited human studies suggest LA is most efficacious in situations where blood triglycerides are markedly elevated. LA is commercially available as dietary supplements and is clinically shown to be safe and effective against diabetic polyneuropathies. LA is described as a potent biological antioxidant, a detoxification agent, and a diabetes medicine. Given its strong safety record, LA may be a useful nutraceutical, either alone or in combination with other lipid-lowering strategies, when treating severe hypertriglyceridemia and diabetic dyslipidemia. This review examines the current evidence regarding the use of LA as a means of normalizing blood triglycerides. Also presented are the leading mechanisms of action of LA on triglyceride metabolism.

KW - AMPK

KW - ChREBP

KW - FGF21

KW - PPARα

KW - SREBP1

UR - http://www.scopus.com/inward/record.url?scp=84947596818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947596818&partnerID=8YFLogxK

U2 - 10.1139/cjpp-2014-0480

DO - 10.1139/cjpp-2014-0480

M3 - Article

VL - 93

SP - 1029

EP - 1041

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

SN - 0008-4212

IS - 12

ER -